Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
116.58
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
September 22, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
September 22, 2023
From
Merck & Co., Inc.
Via
Business Wire
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
September 20, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress...
Via
FinancialNewsMedia
Merck & Co Inc. (NYSE: MRK) Highlighted for Surprising Price Action
August 23, 2023
Via
Investor Brand Network
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
September 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
September 19, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
September 15, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
September 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
September 07, 2023
From
Merck & Co., Inc.
Via
Business Wire
Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics
September 05, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
From
Merck & Co., Inc.
Via
Business Wire
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
August 29, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Citi 18th Annual BioPharma Conference
August 29, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
August 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
August 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
August 24, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
August 18, 2023
From
Merck & Co., Inc.
Via
Business Wire
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
August 04, 2023
Via
Investor Brand Network
Exposures
Product Safety
Rising Dividend Make Zoetis a Doggone Winner
August 03, 2023
Investors that typically focus on other large cap pharmaceutical plays may wish to consider an alternative bet on pets with shares of Zoetis.
Via
MarketBeat
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
August 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Second-Quarter 2023 Financial Results
August 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
7 Best Cancer Stocks to Invest in Now
July 28, 2023
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.
Via
MarketBeat
Topics
Death
Exposures
Death
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
July 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
July 27, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
July 26, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Fourth-Quarter 2023 Dividend
July 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive European Union CHMP Opinion for Gefapixant
July 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
July 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.